Form 4: Anavex Life Sciences PFO Acquires Shares Through Option Vesting
SEC Form 4
Sandra Boenisch, PFO & Treasurer of Anavex Life Sciences Corp., acquired 12,500 shares of common stock through option vesting related to a performance milestone.
Summary
- Sandra Boenisch, the PFO & Treasurer of Anavex Life Sciences Corp., filed a Form 4 indicating a change in beneficial ownership.
- On April 28, 2025, Boenisch acquired 12,500 shares of common stock through the vesting of a stock option.
- The option, granted on March 31, 2023, vests in four equal tranches based on performance milestones.
- The vesting of these 12,500 shares was triggered by the completion of enrollment in the ANAVEX3-71 Phase 2 clinical trial in Schizophrenia.
- The exercise price of the option is $8.57.
- Following the transaction, Boenisch directly owns 12,500 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects a routine transaction related to executive compensation and the achievement of a clinical trial milestone, which is a positive development but not significantly impactful on its own.
Positives
- The completion of enrollment in the ANAVEX3-71 Phase 2 clinical trial in Schizophrenia triggered the vesting of the stock option, suggesting progress in the company's clinical development program.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership. It reflects the company's incentive structure and alignment of management's interests with shareholders.
Stakeholder Impact
- Shareholders may view the vesting of options as a positive sign, indicating progress in the company's clinical trials.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Reporting person was granted an option to purchase 50,000 shares of common stock. |
| 04/28/2025 | Transaction date: Acquisition of 12,500 shares through option vesting. |
| 04/30/2025 | Date of signature on the Form 4. |
| 03/31/2033 | Expiration date of the stock option. |
Keywords
Form 4, Beneficial Ownership, ANAVEX Life Sciences, AVXL, Sandra Boenisch, Stock Option, Vesting, ANAVEX3-71, Schizophrenia, Clinical Trial
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.